What does the Series E funding mean?

Scipio bioscience receives Series A funding of € 6 million for the development and introduction of a sample preparation solution for single cell RNA sequencing

Paris-based biotech company Scipio bioscience, which is developing a new technology for single-cell sequencing, announced today that an international consortium has closed a Series A financing round of € 6 million. The consortium is led by M Ventures (Amsterdam, Netherlands), the corporate venture capital arm of Merck KGaA. The previous investors, Quadrivum I from Seventure Partners (Paris, France) and the High-Tech Gründerfonds (Bonn, Germany), participated in the, together with the new investors Financière Arbevel (Paris, France) and investiere (Zurich, Switzerland) Financing round.

There is a great and unmet need for cost effective methods of single cell sequencing. The availability of such methods will lead to a global growth of the single cell market in basic research as well as in clinical research. Scipio bioscience develops pioneering solutions for cost-effective single-cell sample preparation for sequencing. We offer the team our full support in developing a much-needed solution based on the company's disruptive technology and positioning it as a major player in the field of single cell biology.

Arnaud Autret, Investment Principal at M Ventures.

We're excited that our seed funding for Scipio's deep tech project has helped advance the company's disruptive technology into a potentially game-changing practice. We look forward to the next phases of this development.

Philippe Tramoy, partner at Seventure Partners' SeedFonds Quadrivium 1

We believe that our user-friendly process, which does not require any specific equipment and is suitable for any laboratory bench, enables thousands more scientists to perform single-cell RNA sequencing. This high availability will change the approach to solving biological questions and will ultimately be of great benefit both in basic research and in clinical applications. We are very pleased to initiate the cooperation for the beta test of our kit. We will start with the laboratories of the ICM (Institute for Brain and Spinal Cord, Paris, France), as the interactions so far with their world-class teams and central facilities have been extremely fruitful. Our goal is to expand our collaborations to include leading European research institutes.

Professor Stuart Edelstein, President & CSO Scipio

The € 6 million Series A funding supports the final development of the single-cell RNA sequencing kit
as well as marketing and business development measures in preparation for the market launch in 2022.

About Scipio bioscience
Scipio bioscience is developing a new generation of single cell sequencing solutions to meet the growing needs of clinical and basic research laboratories. The patented technology is based on an innovative chemical approach developed by the company's President and Co-Founder, Professor Stuart Edelstein, a world-renowned biophysicist. Pierre Walrafen, PhD, CEO and also co-founder of Scipio bioscience, leads a team of scientists with expertise in molecular biology, chemistry and bioinformatics. The company, based in the iPEPS-ICM incubator of the Institute for Brain and Spinal Cord (ICM, Pitié-Salpêtrière Hospital, Paris) developed the protocol from the first feasibility studies to a prototype for the beta test by cooperating research teams. Scipio Bisocience was supported by a grant from the Région Île-de-France and the Program d’Investissement d’Avenir, which is run by the BPI France. More information is available at www.scipio.bio

Scipio bioscience
Pierre Walrafen, CEO
T: + 33 1 57 27 41 15
Corporate Legal Advisers: Cabinet Carrel, Alexandra Carrel, Vincent Baudouin and Camille Lefert

Newcap Media
Annie-Florence Loyer
[email protected]

About M Ventures
M Ventures is the strategic corporate venture capital arm of Merck. Its mission is to invest in innovative technologies and products with potentially significant effects on the company's core business areas. M Ventures, headquartered in Amsterdam with offices in the US and Israel, invests in transformative concepts from great entrepreneurs around the world. M Ventures plays an active role in its portfolio companies and works with entrepreneurs and co-investors to turn innovations into commercial success.

M Ventures
Arnaud Autret
[email protected]
Corporate Legal Advisers: Dechert LLP, Anne-Charlotte Rivière and Johann Gandilhon

About the Quadrivium 1 Seed Fund
The Quadrivium I Seedfonds is one of the venture funds managed by Seventure Partners. This fund finances French companies in the seed round (FNA - Future Investment Program) in the fields of life sciences and digital technologies belonging to the academic cluster around UPMC, University of Paris II, University of Paris IV, National Museum of Natural History, IRCAM, ENSCI, Technical University of Compiègne, CNRS, Curie Institute, Pierre Gilles de Gennes Foundation, Voir et Entendre Foundation and Paris Sciences et Lettres (PSL).

Quadrivium 1
Philippe Tramoy
[email protected]
Corporate Legal Advisers: Fiducial Legal by Lamy, Misha Raznatovich and Clotilde Mouchel

About Seventure Partners
With a managed net exposure of € 750 million as of the end of 2018, Seventure Partners is one of the leading venture capital companies in Europe. Seventure Partners has been investing in innovative companies with high growth potential in two areas since 1997: life sciences in Europe, Israel, Asia and North America, and digital technologies in France and Germany. The investment amounts range from € 500,000 to € 10 million per round or up to € 20 million per company from the early to the late phase. Seventure Partners is a subsidiary of Natixis Investment Managers. Natixis is a subsidiary of Groupe BPCE, the second largest banking group in France.

More details can be found at www.seventure.fr/en or on Twitter: @seventurep

About Financière Arbevel
Financière Arbevel is an entrepreneurial investment management company founded in 1997, which has seen significant growth since it was acquired by the current owners in early 2009 - assets under management increased from € 25 million to € 1.9 billion today (of which € 752 million below the Umbrella of SICAV “Pluvalca” with 9 sub-funds). The company currently employs a total of 34 people, 13 of whom are entrusted with fund management / investment research. Financière Arbevel is recognized for its expertise in the field of small and medium-sized capital assets. We are a research-oriented company with a strong focus on fundamental financial and strategy analysis, close relationships with top management of listed companies (more than 1,000 meetings in the past year) and the permanent search for new investment fields with structural growth opportunities. Digitization, Fintech, Industry 4.0 or the aging of the world population are some of our preferred investment areas. We ensure that we closely follow the latest developments in this area by attending numerous conferences, trade fairs and sector-specific themed events, as well as holding regular discussions with the management of listed companies. Our DNA in the small and medium-sized capital area is spread across numerous strategies of the PLUVALCA fund family with a cross-investment approach that includes our core equity funds, thematic equity funds, bond funds and diversified / flexible allocation funds). Financière Arbevel was hired by the Norwegian sovereign wealth fund to manage its French equity mandate in 2015. In 2018, Financière Arbevel boosted its development by setting up its first European private equity fund (FCPI form or “Professional Private Equity Investment Fund”) with a crossover approach focusing on unlisted companies in the life sciences and a limited number of biotechnology -Accompanied startups in their development.

Financière Arbevel
Marc Le Bozec
[email protected]

About invest
investiere is the leading European startup investment platform for qualified and institutional investors. A team of investment professionals screen thousands of companies and, after a rigorous due diligence process, present the best investment opportunities on a digital platform. investiere focuses on European high-tech startups. The investiere community consists of more than 4,000 qualified private investors, family offices and pension funds. In addition, numerous companies rely on investiere's expertise in reviewing, selecting and investing in promising startups. With a total investment volume of CHF 100 million since it was founded in 2010, investiere is the most active startup investor in Switzerland. The third largest bank in Switzerland, Zürcher Kantonalbank, is an anchor investor in investiere.

invest Verve Capital
Michael Luetolf
[email protected]

About the high-tech start-up fund
The Seedinvestor High-Tech Gründerfonds (HTGF) finances technology start-ups with growth potential. With a volume of around EUR 900 million spread over three funds and an international partner network, the HTGF has supported almost 600 start-ups since 2005. His team of experienced investment managers and start-up experts supports the young companies with know-how, entrepreneurial spirit and passion. The focus is on high-tech start-ups in the areas of digital business models, industrial tech, life sciences, chemistry and related business areas. External investors have so far invested more than EUR 2.4 billion in more than 1,500 follow-up financing rounds in the HTGF portfolio. In addition, the fund has already successfully sold shares in more than 100 companies.
Investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital, the Fraunhofer-Gesellschaft and the 32 companies.

High-Tech Gründerfonds Maanagement GmbH
Frank Hensel
Schlegelstrasse 2
53113 Bonn
T: +49 228 823001-142
[email protected]